DFFN Diffusion Pharmaceuticals Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

DFFN [NASD]

Diffusion Pharmaceuticals Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.56	Insider Own	0.23%	Shs Outstand	59.63M	Perf Week	-4.35%
Market Cap	66.80M	Forward P/E	-	EPS next Y	-11.62	Insider Trans	0.00%	Shs Float	45.86M	Perf Month	32.53%
Income	-11.60M	PEG	-	EPS next Q	-0.06	Inst Own	8.60%	Short Float	1.20%	Perf Quarter	80.39%
Sales	-	P/S	-	EPS this Y	78.90%	Inst Trans	1.06%	Short Ratio	0.09	Perf Half Y	149.43%
Book/sh	0.52	P/B	2.12	EPS next Y	-4741.70%	ROA	-57.80%	Target Price	-	Perf Year	-49.31%
Cash/sh	0.18	P/C	6.19	EPS next 5Y	-	ROE	-68.60%	52W Range	0.21 - 2.42	Perf YTD	138.77%
Dividend	-	P/FCF	-	EPS past 5Y	58.90%	ROI	-	52W High	-54.55%	Beta	1.36
Dividend %	-	Quick Ratio	9.10	Sales past 5Y	-	Gross Margin	-	52W Low	421.33%	ATR	0.12
Employees	10	Current Ratio	9.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.85	Volatility	8.26% 12.98%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	90.90%	Profit Margin	-	Rel Volume	0.28	Prev Close	1.12
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	5.87M	Price	1.10
Recom	-	SMA20	-5.30%	SMA50	1.25%	SMA200	67.28%	Volume	1,688,829	Change	-1.79%

Mar-21-18

Initiated

H.C. Wainwright

Buy

$1.25

Jul-27-20 08:00AM	Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC GlobeNewswire -13.64%
Jul-07-20 08:00AM	Diffusion Pharmaceuticals Files IND for International Phase 1b/2b COVID-19 Clinical Program With TSC GlobeNewswire
Jul-06-20 07:47PM	3 Coronavirus Penny Stocks With Triple-Digit Upside Potential TipRanks
Jun-11-20 08:00AM	Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of TSC in COVID-19 Patients GlobeNewswire -5.56%
Jun-01-20 08:00AM	Diffusion Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement GlobeNewswire
May-26-20 08:00AM	Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program GlobeNewswire
May-20-20 01:00PM	Diffusion Pharmaceuticals Inc. Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market GlobeNewswire
08:00AM	Diffusion Pharmaceuticals Expands Clinical Trial Program of TSC for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases GlobeNewswire
May-19-20 03:18PM	Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example' Yahoo Finance Video
09:05AM	DFFN: TSC to be Tested as Treatment for ARDS Caused by COVID-19 Zacks Small Cap Research
May-18-20 09:05AM	Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire -17.78%
May-11-20 04:11PM	Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire +20.53%
May-05-20 08:00AM	Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS GlobeNewswire +11.97%
Apr-27-20 08:00AM	Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19 GlobeNewswire +14.07%
Apr-03-20 07:30AM	DFFN: Evaluating TSC as Potential Treatment for ARDS Zacks Small Cap Research
Apr-01-20 08:00AM	Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients GlobeNewswire +61.09%
Mar-24-20 04:05PM	Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the Coronavirus GlobeNewswire
Mar-19-20 07:28AM	Is Diffusion Pharmaceuticals (NASDAQ:DFFN) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Mar-18-20 06:35PM	CORRECTION -- Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update GlobeNewswire
Mar-17-20 04:10PM	Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update GlobeNewswire +9.53%
Mar-12-20 08:00AM	Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer GlobeNewswire -14.97%
Feb-07-20 08:30AM	Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC GlobeNewswire -7.16%
Jan-10-20 08:00AM	Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors GlobeNewswire +6.55%
Dec-30-19 08:00AM	DFFN: Highly Encouraging Data from Run-in Portion of Phase 3 GBM Trial Zacks Small Cap Research
Dec-22-19 06:43PM	Hedge Funds Have Never Been More Bullish On Diffusion Pharmaceuticals Inc. (DFFN) Insider Monkey
Dec-13-19 02:07PM	Diffusion Pharmaceuticals Inc. Announces Closing of $3.5 Million Offering Priced At-the-Market GlobeNewswire
Dec-12-19 09:55AM	CORRECTING and REPLACING Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -24.51%
08:00AM	Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market GlobeNewswire
Dec-11-19 07:21AM	The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga +31.40%
Dec-10-19 04:00PM	Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients GlobeNewswire -7.77%
Nov-20-19 07:25AM	The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga +67.59%
Nov-19-19 04:05PM	Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care GlobeNewswire
Nov-15-19 11:43AM	Diffusion Pharmaceuticals Announces Closing of $4.0 Million Public Offering GlobeNewswire -7.56%
Nov-13-19 09:34AM	Diffusion Pharmaceuticals Announces $4.0 Million Public Offering GlobeNewswire -54.74%
Nov-11-19 08:00AM	Diffusion Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire -18.39%
Oct-17-19 08:30AM	First Patient Enrolled in Diffusion Pharmaceuticals Phase 2 On-Ambulance Clinical Trial with TSC for the Treatment of Stroke GlobeNewswire -17.65%
Sep-19-19 11:07AM	Will Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Need To Raise More Money? Simply Wall St.
Sep-03-19 10:30AM	Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire
Aug-15-19 10:15AM	DFFN: Positive Safety Data for Dose Escalation Portion of Phase 3 GBM Trial Zacks Small Cap Research
Aug-08-19 05:15PM	Diffusion Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-23-19 08:30AM	Diffusion Pharmaceuticals Reports Favorable Safety Data for Dose-Escalation Run-in of Phase 3 INTACT Study in Glioblastoma Multiforme Patients GlobeNewswire
Jul-11-19 03:21PM	The Diffusion Pharmaceuticals (NASDAQ:DFFN) Share Price Is Down 98% So Some Shareholders Are Very Salty Simply Wall St.
May-28-19 04:05PM	Diffusion Pharmaceuticals Inc. Announces Closing of $6.45 Million Offering Priced At-the-Market GlobeNewswire
May-24-19 09:00AM	Diffusion Pharmaceuticals Inc. Announces $6.45 Million Registered Direct Offering & Private Placement GlobeNewswire -23.27%
May-23-19 07:30AM	Diffusion Pharmaceuticals Receives Notice of Intention to Grant a Patent Related to Use of TSC in Combination with tPA in Ischemic Stroke from European Patent Office GlobeNewswire
May-13-19 02:45PM	DFFN: Phase 2 Study of TSC in Stroke to Start in Summer 2019 Zacks Small Cap Research -7.44%
May-09-19 04:05PM	Diffusion Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-17-19 10:00AM	DFFN: Data from Initial 8 Patients in Phase 3 GBM Trial Expected in mid-2019 Zacks Small Cap Research
Mar-20-19 09:00AM	Diffusion Pharmaceuticals Reports 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-08-19 05:08PM	4 Stocks Join Ben Graham Net-Net Screener Friday GuruFocus.com -28.57%
Feb-11-19 04:00PM	Poster Presented at International Stroke Conference Describing Diffusions On-Ambulance Phase 2 Trial with TSC for Treating Acute Stroke GlobeNewswire -9.64%
Jan-22-19 01:55PM	How Does Investing In Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Impact The Volatility Of Your Portfolio? Simply Wall St. -6.11%
Jan-04-19 09:00AM	Diffusion Pharmaceuticals Chief Executive Officer David Kalergis to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +12.06%
Jan-03-19 09:00AM	Diffusion Pharmaceuticals Executes Successful NASDAQ Compliance Plan: Company Will Remain Listed on NASDAQ Stock Market GlobeNewswire -5.24%
Dec-18-18 06:55AM	Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals ACCESSWIRE -19.50%
Dec-17-18 01:30PM	4 Stocks Providing Investor Opportunity Right Now ACCESSWIRE
09:55AM	U.S. Patent Office Awards Diffusion Exclusive Rights for Use of TSC in Conjunction with Only FDA-Approved Stroke Therapeutic GlobeNewswire
Dec-13-18 02:00PM	Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan GlobeNewswire -5.44%
Dec-10-18 10:15AM	DFFN: Phase 2 Clinical Trial of TSC in Acute Stroke to Commence in 2019 Zacks Small Cap Research -15.75%
Nov-15-18 09:15AM	Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology GlobeNewswire
Nov-14-18 09:00AM	Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Oct-15-18 12:00PM	Diffusion Pharmaceuticals Chief Financial Officer William Bill Hornung to Present at 2018 BIO Investor Forum GlobeNewswire
Sep-25-18 09:00AM	Diffusion Names William (Bill) Hornung Chief Financial Officer GlobeNewswire -9.96%
Sep-12-18 09:00AM	FDA Approves Start of Innovative On-Ambulance Phase 2 Clinical Trial for Treatment of Acute Stroke by Diffusion Pharmaceuticals GlobeNewswire +13.21%
Aug-29-18 08:00AM	Diffusion Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-16-18 02:00PM	DFFN: Enrollment Continues in Phase 3 Trial of TSC in GBM Zacks Small Cap Research -6.10%
Aug-13-18 08:30AM	Diffusion Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire +5.69%
Jun-12-18 08:30AM	Diffusion Pharmaceuticals Announces Validation of European Patent for Oral Formulations of TSC GlobeNewswire
May-29-18 01:04PM	CORRECTION: Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
May-15-18 04:45PM	DFFN: Preparing for Phase 2 Clinical Trial of TSC in Acute Stroke Zacks Small Cap Research
May-10-18 04:05PM	Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire -6.90%
Apr-19-18 04:45PM	DFFN: Enrollment in Phase 3 GBM Trial Continuing Zacks Small Cap Research
Apr-03-18 04:00PM	Diffusion Pharmaceuticals to Present at The MicroCap Conference ACCESSWIRE
07:30AM	Diffusion Pharmaceuticals Reports 2017 Financial Results and Provides Business Update GlobeNewswire
Feb-22-18 10:00AM	DFFN: Phase 3 GBM Trial Underway; Planning for Phase 2 Trial in Stroke Zacks Small Cap Research
Feb-06-18 04:00PM	Diffusion Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire
Feb-01-18 08:15AM	Diffusion Pharmaceuticals Announces Allowances of Two U.S. Patent Applications GlobeNewswire +6.56%
Jan-29-18 04:00PM	Diffusion Pharmaceuticals Announces First Patient Dosed in Phase 3 Trial with TSC in Inoperable Glioblastoma Multiforme GlobeNewswire
Jan-24-18 07:30AM	Abstract Outlining Pre-Hospital Stroke Study with Diffusion Pharmaceuticals TSC To Be Presented at the International Stroke Conference GlobeNewswire
Jan-18-18 01:54PM	Diffusion Pharmaceuticals Inc (DFFN): Shoring up the Balance Sheet by Selling Stock Comes with a Price SmarterAnalyst -35.63%
06:00AM	Diffusion Pharmaceuticals Announces $12 Million Underwritten Public Offering GlobeNewswire
Jan-10-18 08:00AM	Todays Research Reports on Stocks to Watch: Diffusion Pharmaceuticals and Pain Therapeutics ACCESSWIRE -13.88%
Jan-03-18 08:00AM	Diffusion Pharmaceuticals to Present at the 10th Annual Biotech Showcase Conference GlobeNewswire +11.02%
Jan-02-18 04:09PM	Breaking Down Diffusion Pharmaceuticals Incs (NASDAQ:DFFN) Ownership Structure Simply Wall St.
Dec-27-17 08:00AM	Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme GlobeNewswire +7.14%
Dec-19-17 01:35PM	Interested In Healthcare? Why Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) May Be The Entry Point Simply Wall St.
Dec-08-17 12:43PM	What You Must Know About Diffusion Pharmaceuticals Incs (DFFN) Risks Simply Wall St.
Nov-20-17 08:00AM	Diffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity Rule GlobeNewswire
Nov-16-17 02:00PM	DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM Zacks Small Cap Research
Nov-13-17 08:00AM	Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Oct-18-17 08:20AM	Today's Research Reports on Stocks to Watch: Neothetics, Inc. and Diffusion Pharmaceuticals ACCESSWIRE
Oct-17-17 10:28AM	Diffusion Pharmaceuticals Inc to Initiate Phase 3 Trial in Inoperable GBM; Shares Soar 35% SmarterAnalyst
07:30AM	Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme GlobeNewswire
Oct-10-17 10:00AM	Diffusion Pharmaceuticals to Present at the 2017 BIO Investor Forum GlobeNewswire
Sep-13-17 07:49PM	Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)? Simply Wall St.
Sep-05-17 11:11AM	Diffusion Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-31-17 11:00AM	DFFN: Phase 3 Trial of TSC in GBM to Initiate Before End of 2017 Zacks Small Cap Research
Aug-23-17 07:30AM	Diffusion Pharmaceuticals Names William Hornung Chief Business Officer GlobeNewswire
Aug-14-17 04:01PM	Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Jul-31-17 08:30AM	Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer GlobeNewswire

Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience